Your session is about to expire
← Back to Search
Estrogen
The Effects of Aging and Estrogen on the Pituitary
Phase 2 & 3
Waitlist Available
Led By Janet E Hall, M.D.
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up peak hormone level within 2 hours post gnrh doses
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions
No Placebo-Only Group
Summary
The purpose of this study is to study the effects of aging and estrogen on the brain. Specifically, this study will examine how the hypothalamus signals the pituitary gland to secrete reproductive hormones and how that changes with aging.
Eligible Conditions
- Healthy Subjects
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ peak hormone level within 2 hours post gnrh doses
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~peak hormone level within 2 hours post gnrh doses
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Effect of Estrogen on Pituitary Response to GnRH
Pituitary Response to GnRH
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Young postmenopausal womenExperimental Treatment3 Interventions
intervention: graded doses of GnRH following NAL-GLU GnRH antagonist administration with or without transdermal estrogen patch
Group II: Older postmenopausal womenExperimental Treatment3 Interventions
intervention: graded doses of GnRH following NAL-GLU GnRH antagonist administration with or without transdermal estrogen patch
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Gonadorelin
FDA approved
Estradiol
FDA approved
Find a Location
Who is running the clinical trial?
Massachusetts General HospitalLead Sponsor
3,025 Previous Clinical Trials
13,413,849 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,800 Previous Clinical Trials
28,193,655 Total Patients Enrolled
Janet E Hall, M.D.Principal InvestigatorMassachusetts General Hospital
10 Previous Clinical Trials
26,712 Total Patients Enrolled